MedTrace Logo

Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2

NCT02178059 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-03-01

Study results available
· View outcomes & findings →

Summary

Relative bioavailability study to compare inhalation of Terbutaline Sulphate 1,5mg via current version of Turbuhaler with inhalation via a new version

Conditions

  • Healthy Volunteers

Interventions

DRUG

terbutaline sulphate delivered dose

0.4 mg terbutaline sulphate (delivered dose) per inhalation

DRUG

terbutaline sulphate metered dose

0.5 mg terbutaline sulphate (metered dose) per inhalation

Sponsors & Collaborators

Principal Investigators

  • Amitava Ganguli, MB ChB, MRCP · Quintiles London United Kingdom

  • Göran Eckervall, MD · Astrazeneca Mölndal, Sweden

  • Ola Beckman, MD · Astrazeneca Mölndal, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02178059 on ClinicalTrials.gov